# SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma

> clinical trial · VERIFIED · 2026-06-25

Status: NOT_YET_RECRUITING · Sponsor: Hebei Medical University Fourth Hospital · Condition: HCC - Hepatocellular Carcinoma

- Company: Hebei Medical University Fourth Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07668570

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.